NX-2127 free base · Synonyms: NX 2127 · NX2127

NX-2127 is an orally and potent BTK inhibitor.

For research use only. Not for human or veterinary use.

Target PROTACs Btk

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

NX-2127 structure

CAS No.: 2416131-46-7

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 500.00	BP-02011-250mg	In stock	Get quote
500 mg	USD 900.00	BP-02011-500mg	In stock	Get quote
1 g	USD 1,400.00	BP-02011-1g	In stock	Get quote
2 g	USD 2,350.00	BP-02011-2g	In stock	Get quote
5 g	Inquire	BP-02011-5g	In stock	Inquire

Custom Size Bulk Inquiry

Description

NX-2127 is an orally and potent BTK inhibitor, inducing degradation of the mutated BTKC481S in cells. NX-2127 inhibits proliferation of BTKC481S mutant TMD8 cells. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.

Biological activity

Zelebrudomide (NX-2127) is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

Identifiers

SMILES: O=C1C(CCC(N1)=O)N2C(C3=C(C=CC(N4CC[C@H](C4)CN5CCC(CC5)C(C=C6)=CC=C6NC7=NC(N8CCCCC8)=CN=C7C(N)=O)=C3)C2=O)=O
InChIKey: XLWJWCMQMBVNSG-ACXKHFGCSA-N

Specifications

MW (average): 719.8300
Formula: C₃₉H₄₅N₉O₅
CAS No.: 2416131-46-7
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 3 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Robbins DW, et al. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. Journal of medicinal chemistry. 2024 Feb 22;67(4):2321-2336.

Same target

Search PROTACs

Same research area

Search Cancer